August 18, 2014Clinical Science
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention
Why the study?
Does personalized antiplatelet treatment based on platelet reactivity testing reduce MACE in patients with coronary artery disease undergoing PCI?
Population
798 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Comparison
Personalized antiplatelet treatment where… vs Non-personalized treatment where no change in…
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports personalized antiplatelet therapy in PCI patients; hypothesis-generating and requires randomized confirmation before practice change.
Structured PICO
Does personalized antiplatelet treatment based on platelet reactivity testing reduce MACE in patients with coronary artery disease undergoing PCI?
P
Population
798 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
I
Intervention
Personalized antiplatelet treatment where patients with high on-treatment platelet reactivity (HTPR) received up to four repeated loading doses of clopidogrel or prasugrel
C
Comparator
Non-personalized treatment where no change in treatment strategy was undertaken in patients with HTPR
O
Outcome
Major adverse cardiac events (MACE) at 12-month follow-upcomposite
Personalized antiplatelet therapy guided by platelet reactivity testing significantly reduces MACE and improves net clinical benefit without increasing bleeding in patients undergoing PCI.
Cite This Study
Siller‐Matula et al. (2014) studied this question.